peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GHRP

GHRP-6

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

GHRP-6 is classified as a peptide ligand and is listed with Ligand ID 1093.

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

GHRP-6 is classified as a peptide ligand and is listed with Ligand ID 1093.

Sources[1]iuphar-ligandGHRP-6Name: GHRP-6 Ligand ID: 1093 Type: Peptide[3]pubmedThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)).
Source records
2
Independent studies
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Name: GHRP-6 Ligand ID: 1093 Type: Peptide”

    GHRP-6 · Identity and approval

    iuphar-ligand:1093:745e583a1357:745e583a1357
  2. supports · Source-backed record
    “The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)).”

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Abstract

    pubmed:42395176:9df538e1edba:9df538e1edba

Identity

GHRP-6 is described as a six-amino-acid peptide that stimulates (is a secretagogue for) growth hormone release.

Sources[2]pubmedGrowth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.GHRP-6 is a GH secretagogue hexapeptide
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “GHRP-6 is a GH secretagogue hexapeptide”

    Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. · Abstract

    pubmed:41901314:210d65751c5b:210d65751c5b

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 38 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (19), assurance_score_below_0.72 (17), current_regulatory_source_required (15), extraction_ambiguity (37), high_risk_requires_regulatory_or_two_independent_sources (19), no_direct_support (35)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. GHRP-6 ↗

    iuphar-ligand · published 2026-08-26 · retrieved 2026-08-26T20:13:52Z

  2. Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. ↗

    pubmed · published 2026-03-12 · retrieved 2026-08-26T20:13:52Z

  3. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-17T23:10:15Z

Publication history and provenance

Version 4 · Automated assessment · 2026-08-26T20:13:52Z

09601bcc2ae82bab66024a20dd585f3a9584382e6f9a55e55a92993f6dfd0d30